Japan’s Mochida To Submit NDA In Japan For Epadel Switch OTC Drug
This article was originally published in PharmAsia News
Executive Summary
Mochida Pharmaceutical will submit a new drug application in Japan for hyperlipidemia drug Epadel (eicosapentaenoic) switch drug within the year. Using positive data from clinical trials, the company aims for a rapid approval. Upon approval, Mochida's Epadel partner, Japanese major OTC drug maker Taisho Pharmaceutical plans to expand the product in the health supplements market among health sensitive consumers. (Click here for more - Japanese language